LONDON and ZURICH, November 30, 2016 /PRNewswire/ -- Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces it has signed a share purchase agreement that will allow the acquisition of 100% in G7 Therapeutics, a privately held drug discovery and development company based in Switzerland, for CHF 12 million cash. The strategic acquisition broadens and strengthens Heptares' intellectual property and platform for structure-based drug design and development focused on G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. The combination of Heptares' and G7 Therapeutics' platforms is anticipated to increase Heptares' R&D productivity in terms of generating stabilised GPCRs and high quality GPCR structures that underpin discovery efforts for its proprietary pipeline and for partners. G7 Therapeutics has developed proprietary approaches for stabilising GPCRs (called SaBRE and CHESS), which are different and highly complementary to the StaR® platform developed by Heptares. SaBRE and CHESS are of particular use where the target GPCR is present in very low numbers on cells and the methods are particularly powerful in the numbers of stabilizing mutations that can be identified in a short time for rapidly generating high quality GPCRs. Upon completion of the acquisition, G7 Therapeutics will become a wholly owned Zurich-based subsidiary of Heptares and will be renamed Heptares Zurich. The subsidiary will be led by Fiona Marshall, Chief Scientific Officer at Heptares and at Sosei. Dr Marshall commented: "We are delighted to complete the acquisition G7 Therapeutics. We believe that the platform G7 has developed is truly complementary to our StaR platform and will expand our capacity to explore more of the 'GPCRome' to deliver novel candidates against targeted GPCRs for both our proprietary pipeline and for partnered programmes. We look forward to welcoming its highly talented team into Heptares and further extending our leadership advantage in GPCR-focused SBDD."